Enhanced mineralization potential of vascular cells from SM2α-rankltg mice

Calcified Tissue International

Volumn 91, Issue 6, 2012, Pages 379-386

  Morony, S ^a   Sage, A P ^b   Corbin, T ^a   Lu, J ^c   Tintut, Y ^d   Demer, L L ^c,d  

^a AMGEN INC   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcification; RANKL; SM2 ; Smooth muscle cell; Vascular

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; FORSKOLIN; LEVAMISOLE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHATE; TRANSGELIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANKYLOSIS GENE; AORTA MEDIA; ARTICLE; BLOOD VESSEL CALCIFICATION; BODY FAT; BODY WEIGHT; BONE DENSITY; CALCIUM BLOOD LEVEL; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; HISTOLOGY; IN VIVO STUDY; LEG; LONG BONE; MALE; MINERALIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOPROTEGERIN GENE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE; WILD TYPE;

ALKALINE PHOSPHATASE; ANIMALS; FEMALE; FORSKOLIN; MALE; MICE; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RANK LIGAND; VASCULAR CALCIFICATION;

EID: 84871222459     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9655-9     Document Type: Article

References (35)

1. Newman AB, Naydeck BL, Sutton-Tyrrell K, Feldman A, Edmundowicz D, Kuller LH (2001) Coronary artery calcification in older adults to age 99: prevalence and risk factors. Circulation 104:2679-2684
2. Moe SM, Chen NX (2004) Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95:560-567
3. Tintut Y, Parhami F, Bostrom K, Jackson SM, Demer LL (1998) cAMP stimulates osteoblast-like differentiation of calcifying vascular cells. Potential signaling pathway for vascular calcification. J Biol Chem 273:7547-7553
4. Tintut Y, Patel J, Parhami F, Demer LL (2000) Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102:2636-2642
5. Cheng SL, Shao JS, Halstead LR, Distelhorst K, Sierra O, Towler DA (2010) Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ Res 107:271-282
6. Li X, Yang HY, Giachelli CM (2008) BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 199:271-277
7. Johnson K, Polewski M, van Etten D, Terkeltaub R (2005) Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/-mice. Arterioscler Thromb Vasc Biol 25:686-691
8. Ewence AE, Bootman M, Roderick HL, Skepper JN, McCarthy G, Epple M, Neumann M, Shanahan CM, Proudfoot D (2008) Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res 103:e28-e34
9. Chen NX, O'Neill KD, Duan D, Moe SM (2002) Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62:1724-1731
10. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12
11. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268
12. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474
13. Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, Preissner KT, Hofbauer LC (2004) Localization of osteoprotegerin, tumor necrosis factor-relatedapoptosis-inducingligand, and receptor activator of nuclear factor-kappaB ligand inMonckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 89:4104-4112
14. Browner WS, Lui LY, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631-637
15. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106:1192-1194
16. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109:2175-2180
17. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88:1024-1028
18. Schoppet M, Schaefer JR, Hofbauer LC (2003) Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation 107:e76
19. Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarikoc A, Kilic R, Brueckmann M, Lang S, Zahn I, Vahl C, Hagl S, Dempfle CE, Borggrefe M (2004) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36:57-66
20. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, Lopez-Ongil S, Coll B, Fernandez E, Valdivielso JM (2009) RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 104:1041-1048
21. TsengW,GrahamLS, Geng Y, Reddy A, Lu J, EffrosRB, Demer L, Tintut Y (2010) PKA-induced receptor activator of NF-kappaB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification. J Biol Chem 285:29925-29931
22. Byon CH, Sun Y, Chen J, Yuan K, Mao X, Heath JM, Anderson PG, Tintut Y, Demer LL, Wang D, Chen Y (2011) Runx2-upregulated receptor activator of nuclear factor kappaB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol 31:1387-1396
23. Mizuno A, Kanno T, Hoshi M, Shibata O, Yano K, Fujise N, Kinosaki M, Yamaguchi K, Tsuda E, Murakami A, Yasuda H, Higashio K (2002) Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab 20:337-344
24. Li L, Miano JM, Mercer B, Olson EN (1996) Expression of the SM22alpha promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells. J Cell Biol 132:849-859
25. Huang MS, Sage AP, Lu J, Demer LL, Tintut Y (2008) Phosphate and pyrophosphate mediate PKA-induced vascular cell calcification. Biochem Biophys Res Commun 374:553-558
26. Lepore JJ, Cheng L, Min LuM, Mericko PA, Morrisey EE, Parmacek MS (2005) High-efficiency somatic mutagenesis in smooth muscle cells and cardiac myocytes in SM22alpha-Cre transgenic mice. Genesis 41:179-184
27. Jung K, Lein M, Hosslin K, Grosse A, Roth S, Possinger K, Luftner D (2002) Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. Int J Biol Markers 17:177-181
28. Osako MK, Nakagami H, Koibuchi N, Shimizu H, Nakagami F, Koriyama H, Shimamura M, Miyake T, Rakugi H, Morishita R (2010) Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res 107:466-475
29. Olesen M, Skov V, Mechta M, Mumm BH, Rasmussen LM (2012) No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells. Mol Cell Endocrinol 362:149-156
30. Nam HK, Liu J, Li Y, Kragor A, Hatch NE (2011) Ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) protein regulates osteoblast differentiation. J Biol Chem 286:39059-39071
31. Kerschan-Schindl K, Wendlova J, Kudlacek S, Gleiss A, Woloszczuk W, Pietschmann P (2008) Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men. Exp Clin Endocrinol Diabetes 116:491-495
32. Hofbauer LC, Schoppet M, Schuller P, Viereck V, ChristM(2004) Effects of oral contraceptives on circulating osteoprotegerin andsoluble RANK ligand serum levels in healthy young women. Clin Endocrinol (Oxf) 60:214-219
33. Bord S, Ireland DC, Beavan SR, Compston JE (2003) The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32:136-141
34. Bashir A, Mak YT, Sankaralingam S, Cheung J, McGowan NW, Grigoriadis AE, Fogelman I, Hampson G (2005) Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. Steroids 70:847-855
35. Loncar G, Bozic B, Cvorovic V, Radojicic Z, Dimkovic S, Markovic N, Prodanovic N, Lepic T, Putnikovic B, Popovic-Brkic V (2010) Relationship between RANKL and neuroendocrine activation in elderly males with heart failure. Endocrine 37:148-156